NCT00038597View on ClinicalTrials.gov

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2001

Primary Completion Date

May 7, 2004

Study Completion Date

May 7, 2004

Conditions
Myelogenous Leukemia, Chronic
Interventions
DRUG

SCH66336

Trial Locations (1)

77030

MDAnderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00038597 - Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) | Biotech Hunter | Biotech Hunter